Lymphoma
A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1)
Who can joinAdults
Age18–99 years
Kind of studyPhase 1: first tests of safety
What it testsA medicine
The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.
Where to go
26 hospitals in India taking patients for this trial.
Omega Cancer HospitalsVisakhapatnam, Andhra PradeshDirections ↗
Post Graduate Institute of Medical Education & ResearchChandigarh, ChandigarhDirections ↗
Cellcure Care Cancer Pvt LtdAhmedabad, GujaratDirections ↗
HCC Happiness Care and Cure Multispeciality HospitalAhmedabad, GujaratDirections ↗
Shankus Hospital Pvt. Ltd.Ahmedabad, GujaratDirections ↗
Unique HospitalSurat, GujaratDirections ↗
Kiran Multi Speciality HospitalSurat, GujaratDirections ↗
Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical SciencesRohtak, HaryanaDirections ↗
Super Specialty Hospital (G.M.C) SrinagarSrinagar, Jammu and KashmirDirections ↗
KLES Dr Prabhakar Kore Hospital and MRCBelagavi, KarnatakaDirections ↗
Amrita Institute of Medical Sciences (AIMS)Kochi, KeralaDirections ↗
Sujan Surgical Cancer Hospital and Amravati Cancer FoundationAmravati, MaharashtraDirections ↗
Kolhapur Cancer CentreKolhāpur, MaharashtraDirections ↗
Mumbai Onco Care CentreMumbai, MaharashtraDirections ↗
All India Institute of Medical SciencesNagpur, MaharashtraDirections ↗
HCG Manavata Cancer CentreNashik, MaharashtraDirections ↗
Deenanath Mangeshkar Hospital & Research CenterPune, MaharashtraDirections ↗
Sahyadri Super Specialty HospitalPune, MaharashtraDirections ↗
Sushrut HospitalPune, MaharashtraDirections ↗
Armed Forces Medical CollegePune, MaharashtraDirections ↗
Sunact Cancer Institute Pvt. LtdThane, MaharashtraDirections ↗
Rajiv Gandhi Cancer Institute and Research CentreDelhi, National Capital Territory of DelhiDirections ↗
All India Institute of Medical SciencesDelhi, New DelhiDirections ↗
Sparsh Hospital and Critical Care (P) Ltd.Bhubaneswar, OdishaDirections ↗
MNJ Institute of Oncology & Regional Cancer CentreHyderabad, TelanganaDirections ↗
Tata Medical CenterKolkata, West BengalDirections ↗
Registry summary (technical)
An open-label, first-in-human, Phase 1 study in adult patients with relapsed advanced lymphomas will be done to assess AUR108 safety, tolerability, pharmacokinetics, pharmacodynamics, and optimal biological dose.
Sponsor: Aurigene Discovery Technologies Limited
NCT05984147 on ClinicalTrials.gov
Last updated on the registry 17 Apr 2026 · read by us 20 Oct 2026